CDK4 and neoplasm: Already available results show that patients post CDK4/6i have a significantly higher tumor mutation burden compared to patients not pretreated with the same drugs (median 2.92 vs. 1.67, p < 0.0001), and higher frequency of ESR1 alteration [42].